PQRI Case Study (6): Packaging Line GMP Optimization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PQRI Case Study (6): Packaging Line GMP Optimization
The sixth in a series of eight case studies from the Product Quality Research Institute focuses on packaging line GMP optimization.


Pharmaceutical Technology
pp. 46-48

The risk analysis


Table I: Sample severity categories.
The assessment effort required that potential product defects from any given packaging operation be defined and graded for severity, frequency, and on the ability of the operation and/or an operator to detect the defect. Tables I and II summarize the definitions and categories applied for severity and frequency. Defect detection was categorized and graded on a 0-to-4 scale to reflect a detection capability of "none" (unable to detect) to "always" detect.

A team of packaging subject-matter experts, and local site packaging engineers familiar with the subject packaging lines under assessment, worked to collect relevant data about the packaging line. All operations involved with the line function (e.g., equipment, procedures) were listed and all corresponding potential failures were then listed. For each potential failure, the team worked to understand its potential impact on packaging operations and then worked to assign a severity category. Following severity classification, the team reviewed the dominant causes relevant to the defined potential failure and assigned each a frequency category.


Table II: Sample frequency categories.
For each potential failure, all safeguards (e.g., detection capabilities) were reviewed and a detection capability was assigned. For determinations of severity, frequency, and detection, all relevant data was taken into consideration, to include maintenance and operation logs, batch records, deviation investigations, customer complaint records, and so forth.

In the FFEA model, the calculated frequency (F) is combined with the ability to detect (D) and then plotted against severity (S) as follows:





Table III: Resulting work product (sample).
The resulting work output from this assessment was recorded in tabular form. Table III shows an excerpt of the resulting work product.


Figure 1: Risk matrix.
Using the collected tabular information, a risk matrix was assembled (see Figure 1). In Figure 1, items A through D from Table III are noted to reflect their calculated frequency. The risk matrix helps to visually prioritize the results from the risk analysis. In this case study, item "A" would get immediate action to eliminate or reduce the risk. Items "B" and "D" would be evaluated and actions would be taken if practical and appropriate to reduce or eliminate risk. No actions would be required for item "C".


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here